Biotech Roadmap in 2021 Has Led to Some Huge Hedge Fund Losses
Biotech stocks have plummeted in 2021 after soaring last year amid excitement over the development of a COVID-19 vaccine, taking a toll on some hedge funds.
The sector is being countered by concerns Congress will move to cover up drug pricing and the rise of early-stage biotech stocks like IPO market boom.
Percept Advisors, a popular biotech hedge fund that manages about $9 billion, has lost about 30% this year through November in its main fund, investors say, investors say. know. A hedge fund managed by OrbiMed Partners, which invests more than $18 billion in healthcare in the public and private markets, has lost more than 40% in the year to November, people familiar with the matter said. fund said. Both funds have made great returns over the past two years.
Meanwhile, a hedge fund run by San Francisco-based Logos Capital, which manages about $1.4 billion, is down more than 25% over the period, others said. The cormorant asset manager lost 10% in November alone, adding to its double-digit loss earlier in the year.
“It has been a very challenging year,” said Bihua Chen, founder of Cormorant, which focuses on small biotech companies.
An expanded version of this report appears on WSJ.com.
Also popular on WSJ.com:
Apple’s iPhone successor is in the spotlight.
US intelligence says China is looking for its first military base on Africa’s Atlantic coast.
Source link Biotech Roadmap in 2021 Has Led to Some Huge Hedge Fund Losses
